Final Program

SUNDAY • MAY 15 47
216 Physician Assessment of Pre-Test Probability of Malignancy
Out Performs a Validated Nodule Prediction Model but Does
Not Lead to Better Guideline Adherence/N.T. Tanner, A.
Vachani, A. Porter, G.A. Silvestri, Charleston, SC, p.A1286
217 Modeling the Utility of a Bronchial Genomic Classifier on
Procedure Utilization in Patients with Suspected Lung
Cancer/A. Vachani, E. Parsons, D. Whitney, J.S. Ferguson, M.
Lenburg, G.A. Silvestri, A. Spira, Philadelphia, PA, p.A1287
218 Emphysema and Coronary Artery Calcifications on Lung
Cancer Screening Computed Tomography (CT) Scans: A
Potential Missed Opportunity?/A.J. Ghosh, M. Pirzadeh, A.
Rebello, K. Steiling, H. Kathuria, C.C. Reardon, R.S. Wiener, A.J.
Walkey, K.A. Sloan, Boston, MA, p.A1288
219 Differentiating Coccidioidomycosis from Lung Cancer in High
Risk Individuals/V. Ifeacho, O. James, A. Ryazantsev, M. Risco,
G. Rubiaco, K. Almodovar, D. Upadhyay, Fresno, CA, p.A1289
220 Incidental Pulmonary Nodule Committee in a Community
Hospital/O. Kouskov, E. Shochat, M. Schoolfield, A. Falcone, R.
Sandow, C. Duncan, P. Montgomery, Boise, ID, p.A1290
221 Verification of Mayo Clinic Formula to Determine Lung Cancer
Probability Among Patients Living in Tuberculosis Endemic
Areas/S. Saenghirunvattana, C. Saenghirunvattana, M.C.
Gonzales, K. Sutthisri, C. Siangpro, Bangkok, Thailand, p.A1291
222 A Preliminary Comparison Study of Bioconductance
Measurement with 18FDG-PET in Evaluation CT Detected Lung
Lesion Suspicious for Lung Cancer/D. Yang, J. Li, X. Gong, R.
Yung, C. Bai, Shanghai, China, p.A1292
223 Incomplete and Inappropriate Recommendations by
Radiologists for Small and Stable Lung Nodules/S.B. Zeliadt,
K.W. Hammond, J.E. Takasugi, L.C. Feemster, R. Laundry, E.H.
Pham, P.A. Greene, S. Dawadi, L.F. Reinke, C.D. Helfrich, D.H.
Au, Seattle, WA, p.A1293
224 Availability of Resources and Processes of Care for Pulmonary
Nodule Evaluation: A National Survey of American Thoracic
Society Clinicians/J. Iaccarino, J. Simmons, C.G. Slatore, M.K.
Gould, R.S. Wiener, Boston, MA, p.A1294
225 Analytical Performance of a Bronchial Genomic Classifier/D.
Whitney, Z. Hu, J. Anderson, M. Cao, C. Ho, Y. Choi, J. Huang, R.
Frink, K. Porta-Smith, R. Monroe, G. Kennedy, P.S. Walsh, South
San Francisco, CA, p.A1295
A31
THEMATIC POSTER SESSION
ASTHMA THERAPY: GLUCOCORTICOIDS
AND BEYOND
9:00 a.m. - 4:15 p.m. MOSCONE CENTER
Viewing: Posters will be on display for entire session.
Area A, Hall D (North Building, Lower Level)
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators
Facilitator:
P1
P2
P3
P4
P5
P6
P7
P8
P9
Facilitator:
P10
P11
P12
P13
K. Asano, MD, Kanagawa, Japan
Treatment with Novel Retinoid X Receptor Partial Agonist
Attenuates Eosinophilic Airway Inflammation and Airway
Hyperresponsiveness/U. Fujii, A. Kanehiro, N. Miyahara, N. Oda,
D. Morichika, A. Taniguchi, G. Ikeda, H. Nakayama, K. Waseda, E.
Murakami, H. Kakuta, M. Kataoka, K. Kiura, M. Tanimoto,
Okayama, Japan, p.A1296
A Soluble Fibre Challenge Reduces Airway Inflammation in
Asthma/L.G. Wood, I. Halnes, K. Baines, L. McDonald-Wicks, P.G.
Gibson, New Lambton Heights, Australia, p.A1297
Histologic Patterns in Distal Lung Tissue from
Treatment-Resistant Severe Asthma Patients/D. Doberer, H.E.
Trejo Bittar, C. Vitari, S.M. Nouraie, F. Holguin, S.A. Yousem, S.E.
Wenzel, Pittsburgh, PA, p.A1298
FEV1 Improvement with Dupilumab by Different Baseline
Patient Characteristics in Patients with Uncontrolled
Persistent Asthma/J. Corren, S. Spector, B. Zhang, G. Pirozzi, H.
Staudinger, R.R. Evans, N.M.H. Graham, M. Louis-Tisserand, A.
Teper, Los Angeles, CA, p.A1299
Beta-2 Agonists Induce Pro-Inflammatory Mediators in Airway
Epithelial Cells/A.I. Ritchie, A. Singanayagam, S.L. Johnston,
London, United Kingdom, p.A1300
A Sub-Phenotype of Severe Asthma Patients Meet Criteria for
Asthma-COPD Overlap Syndrome (ACOS): A Comparative
Analysis of Clinical Criteria and Biomarkers/A.A. Zeki, S. Louie,
Davis, CA, p.A1301
Metabolomic and Lipidomic Analyses Reveal that Inhalation of
Statins Affects Pulmonary and Systemic Metabolism in the
Rhesus Macaque Non-Human Primate Model/A.A. Zeki, M.
Elbadawi, S. Ott, O. Fiehn, L.A. Miller, A. Haczku, Davis, CA, p.A1302
Exhaled Nitric Oxide as an Indirect Measure of Compliance in
Asthma/K.R. Chapman, T. Sen Dutt, G. Boparai, Toronto, Canada,
p.A1303
Omalizumab Responder Analysis in Chinese Patients with
Moderate-to-Severe Asthma/J. Li, J. Kang, C. Wang, J. Yang, L.
Wang, M. Humphries, S. Greenberg, N. Zhong, Guangzhou, China,
p.A1304
M. Ge, PhD, Davis, CA
Quantitative Acetyl-Proteomic Study on Asthmatic Mice
Highlights the Lysine Acetylation’s Significance in
Anti-Asthma Processes/X. Su, Shen Yang, China, p.A1305
Airway Modification of Acetaminophen and Effect on
Antigenicity to Der p1/R.G. Thomas, D. Fletcher, M.T. Sutton, J.F.
Hunt, B. Gaston, T.L. Bonfield, Cleveland, OH, p.A1306
A GSNOR Inhibitor Blocks HRV Infection of Primary Human
Airway Epithelial Cells /Z. Yang, Y. Bochkov, D.R. Voelker, M.W.
Foster, L.G. Que, Durham, NC, p.A1307
Type 2 Immune Therapies for Severe Asthma: Overlapping
Suitability Leads to Further Questions/J.A. Chen, D.J. Jackson,
London, United Kingdom, p.A1308
SUNDAY MORNING
ATS 2016 • San Francisco